Výsledky vyhledávání - "Helen Nicely"

Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis

Autor: Tammy Wu, Yicheng Yang, Fen Du, Wenyu Ye, Yu Chen, Jinghu Li, Jie Zhang, Helen Nicely, Russel Burge

Publikováno v: ClinicoEconomics and Outcomes Research: CEOR

Yicheng Yang,1 Fen Du,2 Wenyu Ye,3 Yu Chen,4 Jinghu Li,5 Jie Zhang,6 Helen Nicely,7 Russel Burge8 1Patient Outcomes and Real World Evidence, Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, 2Pharmacoeconomics and Outcomes Research, Beijing Brainpower P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85a33c1b93897d71f31816f76d4af1b2
http://europepmc.org/articles/PMC4403816

Zobrazit plný text záznamu

Clinical Outcomes following Hematopoietic Stem Cell Transplantation for the Treatment of Mucopolysaccharidosis VI

Autor: Sean Turbeville, Edwin M. Horwitz, Helen Nicely, Paul Veys, Mitchell E. Horwitz, Paul J. Orchard, J. Douglas Rizzo, Carmem Bonfim, Amal Al-Seraihy, Tanya L. Pedersen

Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) is one of approximately 50 known lysosomal storage disorders. MPS VI is characterized by an absence or deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) resulting in accumulat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d298c74d64b93a763d5b7acc008b92e
https://europepmc.org/articles/PMC3367500/

Zobrazit plný text záznamu

Enzyme replacement therapy in the home setting for mucopolysaccharidosis VI: a survey of patient characteristics and physicians' early findings in the United States

Autor: Virginia Proud, Kristin DeMarco, Sean Turbeville, Helen Nicely, Paul Levy, Cynthia J. Tifft

Publikováno v: Journal of infusion nursing : the official publication of the Infusion Nurses Society. 32(1)

Galsulfase, a Food and Drug Administration-approved enzyme replacement therapy for mucopolysaccharidosis VI, is administered once weekly in a hospital setting as a 4-hour intravenous infusion. To improve convenience and alleviate family responsibilit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb44ac2501cef1c5b9e0c1ac2911b254
https://pubmed.ncbi.nlm.nih.gov/19142150

Zobrazit plný text záznamu

Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy

Autor: Selim T. Koseoglu, Sean Turbeville, Paul Harmatz, Helen Nicely

Publikováno v: International Ophthalmology
International ophthalmology, vol 29, iss 4

MPS VI (mucopolysaccharidosis VI, known as Maroteaux–Lamy syndrome) is a multi-systemic inherited disease, resulting from a deficiency of N-acetylgalactosamine-4-sulfatase, causing accumulation of the glycosaminoglycan (GAG) dermatan sulfate in all

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f889bf90b6c59129420127081f1f65c2
https://pubmed.ncbi.nlm.nih.gov/18418554

Zobrazit plný text záznamu

Mucopolysaccharidosis VI

Autor: Vassili Valayannopoulos, Helen Nicely, Paul Harmatz, Sean Turbeville

Publikováno v: Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, Vol 5, Iss 1, p 5 (2010)

Mucopolysaccharidosis VI (MPS VI) is a lysosomal storage disease with progressive multisystem involvement, associated with a deficiency of arylsulfatase B leading to the accumulation of dermatan sulfate. Birth prevalence is between 1 in 43,261 and 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0596cdfba28f4ea31149334d36aa52a
http://europepmc.org/articles/PMC2873242

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání